Advertisement
Advertisement
November 17, 2026
OCCLUDE Registry Data Published for Boston Scientific’s Obsidio Conformable Embolic
KEY TAKEAWAYS
- Final OCCLUDE registry results included 125 patients treated with Obsidio conformable embolic at 19 United States hospitals.
- Target vessel occlusion was achieved in 100% of cases, with no target vessel rebleeding reported through 30 days.
- Freedom from adverse events was 97.4% at 30 days, and 23.6% of procedures involved adjunctive embolic agents.
November 17, 2026—Boston Scientific announced the publication of data from the OCCLUDE registry evaluating the Obsidio conformable embolic. The final results from the prospective, multicenter real-world study were published by Ketan Y. Shah, MD, et al in the Journal of Vascular and Interventional Radiology.
According to Boston Scientific, the OCCLUDE data included outcomes from 125 patients (age, 18–92 years) who underwent embolization with Obsidio embolic across 19 hospitals in the United States. The technology was used for diverse embolization indications in 19 target vessels, providing a comprehensive overview of the device’s safety and performance.
As outlined in the company’s press release, key findings from the study included:
- 100% occlusion of target vasculature with Obsidio, and no reports of rebleeding in target vessels within the 30-day follow-up period.
- 97.4% freedom from adverse events through 30 days.
- 23.6% of procedures used adjunctive embolics, including beads, coils and gelatin sponges.
Advertisement
Advertisement